Effect of cefixime and cefdinir, oral cephalosporins, on cytochrome P450 activities in human hepatic microsomes

被引:15
|
作者
Niwa, T
Shiraga, T
Hashimoto, T
Kagayama, A
机构
[1] Fujisawa Pharmaceut Co Ltd, Biopharmaceut & Pharmacokinet Res Labs, Yodogawa Ku, Osaka 5328514, Japan
[2] Fujisawa Pharmaceut Co Ltd, Postmarketing Dev Res Ctr, Chuo Ku, Osaka 5418514, Japan
关键词
cefixime; cefdinir; human hepatic cytochrome P450; oral cephalosporin; drug interaction;
D O I
10.1248/bpb.27.97
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The effects of two kinds of oral cephalosporins, cefixime and cefdinir, on cytochrome P450 (CYP) activities in human hepatic microsomes were investigated. Both cefixime and cefdinir at 2 mm concentration neither inhibited nor stimulated CYP1A1/2-mediated 7-ethoxyresorufin O-deethylation, CYP2A6-mediated coumarin 7-hydroxylation, CYP2B6-mediated 7-benzyloxyresorufin O-debenzylation, CYP2C8/9-mediated tolbutamide methylhydroxylation, CYP2C19-mediated S-mephenytoin 4'-hydroxylation, CYP2D6-mediated bufuralol 1-hydroxylation, CYP2E1-mediated chlorzoxazone 6-hydroxylation, CYP3A4-mediated nifedipine oxidation, or CYP3A4-mediated testosterone 6beta-hydroxylation. The free fractions of cefixime and cefdinir in the incubation mixture, which were measured by ultracentrifugation, were 86.1-93.8% and 94.1-97.8%, respectively. These results suggest that both cefixime and cefdinir would not cause clinically significant interactions with other drugs, which are metabolized by CYPs, via the inhibition of metabolism.
引用
收藏
页码:97 / 99
页数:3
相关论文
共 50 条
  • [41] Characterization of the Effect of Upadacitinib on the Pharmacokinetics of Bupropion, a Sensitive Cytochrome P450 2B6 Probe Substrate
    Mohamed, Mohamed-Eslam F.
    Minocha, Mukul
    Trueman, Sheryl
    Feng, Tian
    Enejosa, Jeffrey
    Fisniku, Ogert
    Othman, Ahmed A.
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2021, 10 (03): : 299 - 306
  • [42] Study the effect of 3,4-Methylenedioxy methamphetamine on cytochrome P450 2E1 activity
    Nilchi, Shahin
    Neyshaburinezhad, Navid
    Rouini, Mohammadreza
    Lavasani, Hoda
    Foroumadi, Alireza
    Ardakani, Yalda H.
    BRAZILIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2022, 58
  • [43] Inhibition of cytochrome P450 3A enzyme by Millettia aboensis: its effect on the pharmacokinetic properties of efavirenz and nevirapine
    Nduka, Sunday O.
    Okonta, Mathew J.
    Ajaghaku, Daniel L.
    Amorha, Kosisochi C.
    Ukwe, Chinwe V.
    REVISTA BRASILEIRA DE FARMACOGNOSIA-BRAZILIAN JOURNAL OF PHARMACOGNOSY, 2017, 27 (02): : 228 - 235
  • [44] Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R- and S-warfarin enantiomers
    Yamazaki, H
    Shimada, T
    BIOCHEMICAL PHARMACOLOGY, 1997, 54 (11) : 1195 - 1203
  • [45] In vitro inhibitory mechanisms and molecular docking of 1′-S-1′-acetoxychavicol acetate on human cytochrome P450 enzymes
    Haque, A. K. M. Mahmudul
    Leong, Kok Hoong
    Lo, Yoke Lin
    Awang, Khalijah
    Nagoor, Noor Hasima
    PHYTOMEDICINE, 2017, 31 : 1 - 9
  • [46] Inhibitory Effects of Schisandra Lignans on Cytochrome P450s and Uridine 5′-Diphospho-Glucuronosyl Transferases in Human Liver Microsomes
    Seo, Hyung-Ju
    Ji, Seung-Bae
    Kim, Sin-Eun
    Lee, Gyung-Min
    Park, So-Young
    Wu, Zhexue
    Jang, Dae Sik
    Liu, Kwang-Hyeon
    PHARMACEUTICS, 2021, 13 (03)
  • [47] Effect of Saquinavir-Ritonavir on Cytochrome P450 3A4 Activity in Healthy Volunteers Using Midazolam as a Probe
    Schmitt, Christophe
    Hofmann, Carsten
    Riek, Myriam
    Patel, Arpna
    Zwanziger, Elke
    PHARMACOTHERAPY, 2009, 29 (10): : 1175 - 1181
  • [48] Effect of genetic polymorphism on the inhibition of dopamine formation from p-tyramine catalyzed by brain cytochrome P450 2D6
    Niwa, Toshiro
    Shizuku, Marina
    Yamano, Kaori
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2017, 620 : 23 - 27
  • [49] Use of heterologously expressed human cytochrome P450 1A2 to predict tacrine-fluvoxamine drug interaction in man
    Becquemont, L
    Le Bot, MA
    Riche, C
    Funck-Brentano, C
    Jaillon, P
    Beaune, P
    PHARMACOGENETICS, 1998, 8 (02): : 101 - 108
  • [50] Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug-drug interaction risk assessment
    Venkatakrishnan, K.
    Obach, R. S.
    Rostami-Hodjegan, A.
    XENOBIOTICA, 2007, 37 (10-11) : 1225 - 1256